Patent application number | Description | Published |
20110172177 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 07-14-2011 |
20110245193 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine A | 10-06-2011 |
20110245195 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 10-06-2011 |
20110251151 | COMBINATION COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE - Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine A | 10-13-2011 |
20140018314 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 01-16-2014 |
20150038448 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE - The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A | 02-05-2015 |
20150080330 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS - Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT). | 03-19-2015 |